#228000
ICD+
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| FARBER LIPOGRANULOMATOSIS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative titles; symbols | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| FARBER DISEASE CERAMIDASE DEFICIENCY ACID CERAMIDASE DEFICIENCY AC DEFICIENCY N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Phenotype Gene Relationships | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinical Synopsis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TEXT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| A number sign (#) is used with this entry because Farber lipogranulomatosis is caused by mutations in the ASAH1 gene (613468). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinical Features | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In the few reported cases of Farber disease, manifestations appeared in the first few weeks of life and consisted of irritability, hoarse cry, and nodular, erythematous swellings of the wrists and other sites, particularly those subject to trauma. Severe motor and mental retardation was evident. Death occurred by 2 years of age. The histologic appearance was granulomatous. In the nervous system, both neurons and glial cells were swollen with stored material characteristic of nonsulfonated acid mucopolysaccharide (Abul-Haj et al., 1962). Parental consanguinity had not been identified. However, in 1 case parents had the same family name in ancestors, and 2 of 3 families seen at Children's Hospital, Boston, were of Portuguese extraction. The family with 2 affected sibs had father from the Azores Islands and mother from the Madeira Islands. The parents of the other family were both born in the Azores (Crocker et al., 1967). Clausen and Rampini (1970) proposed that an enzymatic defect in glycolipid degradation is the basic fault. Sugita et al. (1972) suggested that the basic defect is a deficiency of acid ceramidase (AC), also called N-acylsphingosine amidohydrolase (ASAH), which normally catalyzes the synthesis and degradation of ceramide. No activity of this enzyme could be demonstrated in kidney and cerebellum. Antonarakis et al. (1984) described 2 sibs, a 12-week-old girl with classic severe features (subcutaneous periarticular nodules, hoarse cry, failure to thrive, and respiratory insufficiency) and a 10-week-old boy, who presented earlier, with clinical features suggestive of malignant histiocytosis. They died at 6 months and at 12 weeks, respectively. The girl also had hepatosplenomegaly, a relatively unusual feature of Farber disease; of 27 reported cases, 7 had hepatomegaly and 1 had splenomegaly. Thus, Farber disease should be considered in infants with seeming malignant histiocytosis. Because of the 25% recurrence risk and ability to make prenatal diagnosis, assay of ceramidase is important in such cases. Pellissier et al. (1986) studied 2 severely affected sibs born of consanguineous Tunisian parents. Involvement of both the central and peripheral nervous system was documented. Macular cherry red spots were observed in 1. Moser et al. (1989) identified 5 types of Farber lipogranulomatosis. In the classic type 1, the diagnosis can be made almost at a glance by the triad of subcutaneous nodules, arthritis, and laryngeal involvement. When 1 aspect is missing, the possibility of juvenile rheumatoid arthritis, multicentric reticulohistiocytosis, or juvenile hyaline fibromatosis (228600) may be entertained, but ceramidase levels are normal in all of these conditions. Patients with types 2 and 3 survive longer. Liver and lung appear not to be involved. Normal intelligence in many of these patients and the postmortem findings suggest that brain involvement is limited or missing entirely. Moser et al. (1989) stated that several patients with type 3 were 'in relatively stable condition near the end of the second decade.' Type 4 patients present with hepatosplenomegaly and severe debility in the neonatal period and all die before 6 months of age. Massive histiocytic infiltration of liver, spleen, lungs, thymus, and lymphocytes is found at autopsy. Patients of Antonarakis et al. (1984) fell into this group; their case 1 had not been recognized even after postmortem study, and the diagnosis of Farber disease was considered only in retrospect when subcutaneous nodules were noted in a subsequently born sib. Type 5, described by Zarbin et al. (1985) and Eviatar et al. (1986), is characterized particularly by psychomotor deterioration beginning at age 1 to 2.5 years. The family of Zarbin et al. (1985) included 2 affected sisters from a marriage of a Korean national and a Caucasian female; the affected girls may represent a genetic compound. As in the case of Pellissier et al. (1986), macular cherry red spots were noted. The patient of Eviatar et al. (1986) was a black child. Qualman et al. (1987) described a family in which 1 child, a 3-month-old boy, presented with only hepatosplenomegaly and had a fulminant clinical course suggestive of malignant histiocytosis. The second child, a 5.5-month-old girl, had the typical clinical presentation of Farber disease, with hoarseness and painful swollen joints. Visceral involvement was prominent in both, and included a newly described nephropathy with elevated urine ceramide levels. Liver and spleen contained massive histiocytic infiltrates in association with elevated ceramide levels. Lymph nodes also contained histiocytic infiltrates but without the sinusoidal involvement typical of proliferative histiocytic disorders. Nowaczyk et al. (1996) described a 16-week-old female infant with the rare type IV Farber lipogranulomatosis featuring hepatosplenomegaly, macular cherry red spot, and subcutaneous nodules. The patient developed liver dysfunction with jaundice and ascites and myelophthisic anemia because of infiltration of the bone marrow with storage cells. Direct assay of skin fibroblasts confirmed the diagnosis of ceramidase deficiency. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Diagnosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ben-Yoseph et al. (1989) used N-laurylsphingosine deacylase as a substrate for studying the usefulness of plasma specimens for diagnosis and carrier detection of Farber disease. This made a highly sensitive assay because the substrate is cleaved by acid ceramidase at a much faster rate than are other substrates. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mapping | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Farber disease is caused by mutations in the ASAH1 gene, which Li et al. (1999) mapped to chromosome 8p22-p21.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Genetics | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In a patient with Farber disease, Koch et al. (1996) identified a homoallelic thr222-to-lys (T222K; 613468.0001) in the ASAH1 gene. Bar et al. (2001) identified 6 novel mutations in the ASAH gene causing Farber disease: 3 point mutations resulting in single amino acid substitutions, 1 intronic splice site mutation resulting in exon skipping, and 2 point mutations leading to occasional or complete exon skipping. The latter 2 mutations occurred in adjacent nucleotides and led to abnormal splicing of the same exon. Metabolic labeling studies in fibroblasts of 4 patients showed that even though acid ceramidase precursor protein was synthesized in these individuals, rapid proteolysis of the mutated, mature acid ceramidase occurred within the lysosome. For further information on mutations in the ASAH1 gene in patients with Farber disease, see MOLECULAR GENETICS in 613468. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| See Also: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amirhakimi et al. (1976); Cartigny et al. (1985); Farber et al. (1957); Fensom et al. (1979) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| REFERENCES | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||